Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Accenture
Daiichi Sankyo
Mallinckrodt
US Department of Justice
Farmers Insurance
Cantor Fitzgerald
Dow
Deloitte

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,939,518

« Back to Dashboard

Which drugs does patent 7,939,518 protect, and when does it expire?

Patent 7,939,518 protects ZIPSOR and is included in one NDA.
Summary for Patent: 7,939,518
Title:Method of treating post-surgical acute pain
Abstract: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
Inventor(s): Kowalski; Mark M. (Winchester, MA), Young; James L. (Valley Park, MO), Moore; Keith A. (Loveland, OH)
Assignee: Aaipharma Inc. (Wilmington, NC)
Application Number:12/466,491
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,939,518
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 7,939,518

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Depomed Inc ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,939,518

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,623,920 Method of treating post-surgical acute pain ➤ Sign Up
7,662,858 Method of treating post-surgical acute pain ➤ Sign Up
9,561,200 Method of treating post-surgical acute pain ➤ Sign Up
8,110,606 Method of treating post-surgical acute pain ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Cipla
Colorcon
Cerilliant
McKinsey
Baxter
Federal Trade Commission
Express Scripts
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.